Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||RX-5902||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, Supinoxin (RX-5902) decreased nuclear beta-catenin and Mcl-1 expression, induced cell cycle arrest and apoptosis in triple-receptor negative breast cancer cell lines in culture, led to tumor growth inhibition in cell line xenograft and patient derived xenograft (PDX) models (PMID: 31488700).||31488700|